Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560462 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL21095884 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL29560764 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL29561888 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL21063720 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL325083 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL1668148 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL327233 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL12046710 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL29478499 | 0.85 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112586-B2 | Substituted diamine derivatives useful as motilin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-09-26 | — | — | US | claimed |
| US-20050148584-A1 | Novel substituted diamine derivatives useful as motilin antagonists | JOHNSON SIGMOND G (US) | 2005-07-07 | — | — | US | claimed |
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-114195713-B | Method for synthesizing dihydroisoquinoline by catalyzing selective dehydrogenation of tetrahydroisoquinoline | 广东众源药业有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-4259623-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| EP-4048677-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-11 | — | — | US | disclosed |
| WO-2020252222-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252222-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3724188-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118528-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019118528-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2019-06-20 | — | — | WO | disclosed |
| EP-0801067-B1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-6174896-B1 | MUSCARINIC RECEPTOR ANTAGONISTIC ACTIVITY; FOR THERAPY AND PROPHYLAXIS FOR UROLOGIC DISEASES, RESPIRATORY DISEASES OR DIGESTIVE DISEASES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-6017927-A | Quinuclidine derivatives and medicinal composition thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| EP-0801067-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN2 | PRCP 62/4885GAA 277/4885RECQL 2805/4885 |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | PRCP 70/4885GAA 178/4885RECQL 2422/4885 |
| US-20050148584-A1 | Novel substituted diamine derivatives useful as motilin antagonists | MLNR, NPY4R, GIPR | PRCP 1448/4885GAA 1097/4885RECQL 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.